Savient cuts sales force $56m to boost Krystexxa: paradox or paralysis?
This article was originally published in Scrip
Louis Ferrari, Savient Pharmaceuticals' executive vice president and president of North American commercial operations, was named president and CEO on 9 July when the company announced a 35% reduction of its workforce and realignment of its operations to support commercialization of the refractory chronic gout (RCG) therapy Krystexxa (pegloticase).
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.